Group One Trading’s Outlook Therapeutics OTLK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$926 Sell
4,500
-72,100
-94% -$31.2K ﹤0.01% 7223
2025
Q4
$121K Buy
76,600
+71,100
+1,293% +$114K ﹤0.01% 4837
2025
Q3
$5.83K Sell
5,500
-3,500
-39% -$6.05K ﹤0.01% 7465
2025
Q2
$14.4K Hold
9,000
﹤0.01% 6485
2025
Q1
$11K Buy
+9,000
New +$15.8K ﹤0.01% 6197
2024
Q4
Sell
-400
Closed -$2.14K 7777
2024
Q3
$2.14K Buy
+400
New +$2.93K ﹤0.01% 6127

Other funds holding OTLK

Group One Trading's OTLK Position: Q1 2026 in Review

Group One Trading increased its Outlook Therapeutics (OTLK) stake by 207% in Q1 2026, buying an estimated $33.1K and bringing the position to 113,701 shares worth $23.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5848.

Group One Trading first reported a position in OTLK in Q1 2025 and has held it in 5 quarters since. The position peaked at $58.5K in Q4 2025. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Group One Trading held 113,701 shares of Outlook Therapeutics worth $23.4K as of Q1 2026.
  • Group One Trading bought 76,704 Outlook Therapeutics shares in Q1 2026, an estimated $33.1K.
  • Outlook Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #5848 holding.
  • Group One Trading first reported a position in Outlook Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Group One Trading's Outlook Therapeutics position peaked at $58.5K in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.